Supplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer by Matthew T. Campbell (15096440)

“…<p>Flow cytometry of immune cells from serially collected blood samples with evidence of significant decrease in circulating NK cells in: A) Metastatic renal cell carcinoma cohort. …”

Image 4_CXCR7-TAGLN2 protein complex regulates invasion and metastasis in papillary thyroid carcinoma: a potential therapeutic target.tif by Chao Zeng (452370)

“…High expression of both proteins was significantly associated with lymph node metastasis in PTC patients, and a significant positive correlation was observed between CXCR7 and TAGLN2 expression levels. …”

Image 2_CXCR7-TAGLN2 protein complex regulates invasion and metastasis in papillary thyroid carcinoma: a potential therapeutic target.tif by Chao Zeng (452370)

“…High expression of both proteins was significantly associated with lymph node metastasis in PTC patients, and a significant positive correlation was observed between CXCR7 and TAGLN2 expression levels. …”

Image 1_CXCR7-TAGLN2 protein complex regulates invasion and metastasis in papillary thyroid carcinoma: a potential therapeutic target.tif by Chao Zeng (452370)

“…High expression of both proteins was significantly associated with lymph node metastasis in PTC patients, and a significant positive correlation was observed between CXCR7 and TAGLN2 expression levels. …”

Image 3_CXCR7-TAGLN2 protein complex regulates invasion and metastasis in papillary thyroid carcinoma: a potential therapeutic target.tif by Chao Zeng (452370)

“…High expression of both proteins was significantly associated with lymph node metastasis in PTC patients, and a significant positive correlation was observed between CXCR7 and TAGLN2 expression levels. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image 1_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.tif by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Image 2_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.tif by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table 4_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table 1_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table 3_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Table 2_Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.docx by Zhengqing Yu (12641890)

“…Significant heterogeneity was detected in the pooled analysis and meta-regression analysis suggested that participants’ age and the prevalence of diabetes significantly accounted for the heterogeneity.…”

Supplementary file 1_Characteristics, clinical evidence and implementation effects of conditional approvals for drugs in China, a pooled analysis from 2020 to 2023.docx by Li Yang (6520)

“…<p>In late 2019, the conditional approval process for drugs in China transitioned from a pilot project to a formal program. Our study comprehensively analyzed 103 conditional approvals (CAs) authorized by the National Medical Products Administration (NMPA) from 2020 to 2023, specifically focusing on their characteristics, clinical evidence, and implementation effects. …”